<DOC>
	<DOCNO>NCT00246207</DOCNO>
	<brief_summary>The purpose pilot study evaluate safety , tolerability potential effectiveness CONCERTAÂ® ( methylphenidate hydrochloride extended-release tablet ) , central nervous system ( CNS ) stimulant treatment adult Attention Deficit Hyperactivity Disorder ( ADHD ) .</brief_summary>
	<brief_title>CONCERTA ( OROS Methylphenidate Hydrochloride ) Treatment Attention Deficit Hyperactivity Disorder Adults</brief_title>
	<detailed_description>CONCERTA® long-acting form methylphenidate ( CNS stimulant ) . Methylphenidate recognize first-line treatment ADHD child adolescent . It widely acknowledge scientific literature disorder often persist adulthood , associate significant morbidity undesirable outcome . Despite , study conduct investigate efficacy safety stimulant therapy treat ADHD adult . As consequence , drug treatment option adult sufferer ADHD limit . The primary objective pilot , open-label study evaluate safety , tolerability potential effectiveness CONCERTA® ( 18 , 36 , 54 72 mg methylphenidate hydrochloride , administer once-daily ) adult subject Attention Deficit Hyperactivity Disorder ( ADHD ) . Patients treat methylphenidate- amphetamine-containing medication within 4 week screen visit . Once deem eligible , subject start 18 mg CONCERTA® once-daily 3 day , titrate Day 4 36 mg maintain dose 7 day . Depending patient response , dose CONCERTA® continue titrate every 7 day , first 54 mg maximum 72 mg per day , order achieve optimal dose patient . The primary efficacy outcome change baseline end treatment inattention hyperactivity/impulsivity subscale score investigator-rated Conners ' Adult ADHD Rating Scale ( CARRS ) . Safety tolerability monitor throughout study . The study hypothesis stimulant therapy treat adult ADHD safe effective , measure Conners ' Adult ADHD Rating Scale ( CAARS ) score . CONCERTA® take orally , once-daily . Starting CONCERTA® 18 mg 3 day , subject titrate Day 4 36 mg 7 day . Depending response , tolerability clinician 's discretion , dose CONCERTA® continue titrate every 7 day , first 54 mg maximum 72 mg per day ( two 36 mg tablet ) , subject 's optimal dose achieve . The titration period last maximum 24 day .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Have diagnosis Attention Deficit Hyperactivity Disorder ( ADHD ) accord Diagnostic Statistical Manual Mental Diseases ( DSMIV ) obtain via clinical interview confirm Wender Utah Rating Scale ADHD symptom childhood adulthood , symptoms present age 7 year continue meet DSMIV criterion time assessment . ( ADHD diagnose symptom well account another psychiatric disorder . ) investigatorrated CAARS ( Conners ' Adult ADHD Rating Scale ) baseline score great equal 24 Clinical Global Impression Severity baseline score great equal 4 total Montgomery Asberg Depression Rating score baseline less equal 16 . Have treat methylphenidate amphetaminecontaining medication within 4 week screen visit clinically unstable psychiatric condition include follow , limited : acute mood disorder , schizophrenia , bipolar disorder , acute obsessive compulsive disorder , antisocial personality disorder subject mark anxiety , tension , aggression agitation , Autism Asperger 's syndrome diagnosis substance abuse dependence within 6 month prior screen evaluation use psychotropic medication use treat nonADHD psychiatric disorder , dose medication remain stable minimum 4 week prior trial entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>once-day oral tablet</keyword>
</DOC>